ARMP: Bullish Pennant detected on 25 Feb 2026

ARMP is forming a bullish pennant pattern as of Feb 25, 2026, with the stock currently at $11.86 near key resistance at $11.90. The pattern exhibits exceptional technical quality: structure score of 15.0 (maximum), breakout score of 13.0, and volume score of 12.0 for an overall score of 89.65. Volume is 2.79x above the 20-day average at 149,144 shares, confirming conviction. The pennant follows a post-collapse recovery spanning 84 days and was preceded by a three-white-soldiers pattern formed Feb 20 with a 37.4 quality score. Support sits at 6.09, offering substantial downside cushion.

Armata Pharmaceuticals reported positive Phase 2a diSArm results for AP-SA02 in complicated Staphylococcus aureus bacteremia at IDWeek 2025 in October, showing 88% clinical response vs. 58% placebo (p=0.047), with zero non-response/relapse vs. ~25% placebo, and no serious adverse events related to the drug. The company plans a Phase 3 superiority trial in 2026, subject to FDA feedback. Armata commissioned a new 56,000 sq ft cGMP manufacturing facility in Los Angeles on November 10, 2025, including 10,000 sq ft of cGMP clean rooms and automated fill-and-finish suite, with full production runs completed and no issues, positioning the facility to supply multi-phage cocktails for clinical programs and potential Phase 3 AP-SA02 trial in 2026. Upcoming earnings are scheduled for March 19, 2026. Armata secured $4.65 million in non-dilutive Department of Defense funding, increasing total DoD award to $26.2 million.

A successful breakout above the $11.90 resistance level would target $12.64 (conservative measured move), requiring sustained volume above the current 149,144-share level to confirm conviction. The pennant's formation on exceptionally bullish technicals (structure at maximum 15.0, win probability at 80.73%) suggests a potential explosive move if price breaks decisively higher. The invalidation level sits at support of 6.09—a breach below that point would negate the setup entirely. Historical pennant patterns at this quality threshold typically resolve in 1–4 weeks.

ARMP's last quarter EPS was −$0.23 and the next quarter is expected to reach −$0.38, indicating deteriorating profitability despite clinical progress. RSI of 84.43 is significantly overbought (>70), flagging potential pullback risk before continuation higher. The stock's 52-week range of $0.90 to $16.34 shows high volatility, and the recent 97.67% one-month gain has compressed risk/reward near resistance. The company has a 1-year analyst target of $12.00, close to the pattern target, limiting upside surprise. As a clinical-stage biotech, regulatory setbacks on the Phase 3 FDA feedback for AP-SA02 could trigger sharp reversals. Micro-cap liquidity ($286M market cap) amplifies volatility on news flow.